Anthera Pharmaceuticals (ANTH) Earning Somewhat Favorable Press Coverage, Report Finds

Headlines about Anthera Pharmaceuticals (NASDAQ:ANTH) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.3126406427263 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news articles that may have effected Accern’s rankings:

Anthera Pharmaceuticals (NASDAQ:ANTH) traded up $0.03 during mid-day trading on Tuesday, hitting $1.89. The company had a trading volume of 476,000 shares, compared to its average volume of 330,808. Anthera Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $20.24.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.32. During the same period in the previous year, the company posted ($4.85) earnings per share. research analysts forecast that Anthera Pharmaceuticals will post -3.34 earnings per share for the current fiscal year.

A number of research firms have commented on ANTH. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $1.75 price objective (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Anthera Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $5.11.

COPYRIGHT VIOLATION WARNING: “Anthera Pharmaceuticals (ANTH) Earning Somewhat Favorable Press Coverage, Report Finds” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply